Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11254)	8/16/1999 10:35:00 PM
From: Bluegreen	Respond to of 17367

George, remember the big miracle would be if Neuprex did not show clinical benefit. After looking at many of the abstracts from the collaborations I figured Castello would say what he did. Neuprex not showing clinical benefit in Meningo. cases would be like exogenous insulin not affecting blood sugar levels in my opinion. BTW, who is to say the FDA might not hurry things up at this next scheduled meeting? One last thing, why was the FDA also interested in morbidity and ruled it as ethical? Do they have some agenda we haven't thought of yet? Hmmmmmmmmmmm.